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ABSTRACT
Objectives: In this study, the cost-effectiveness of rituximab was evaluated
in comparison with commonly used chemotherapy regimens for patients
with advanced follicular lymphoma (FL), from the perspective of the UK
National Health Service (NHS).
Methods: Results from four randomized controlled trials comparing the
addition of rituximab to chemotherapy regimens: mitoxantrone, chloram-
bucil, and prednisolone (MCP); cyclophosphamide, vincristine, and pred-
nisolone (CVP); cyclophosphamide, doxorubicin, vincristine, and
prednisolone (CHOP); or cyclophosphamide, etoposide, doxorubicin,
prednisolone, and interferon alpha (CHVP + IFNa) versus chemotherapy
alone were used to develop a Markov model. The rates of disease progres-
sion and the duration of treatment effect were obtained from the trial data.
Treatments were compared in two ways: 1) an individual comparison of
rituximab + chemotherapy versus chemotherapy and 2) a multiple treat-
ment comparison using league tables. Economic and clinical outcomes
(quality-adjusted life-years (QALYs)) were estimated over patient lifetimes
and discounted at 3.5% per annum.
Results: In the individual comparison, the addition of rituximab increased
QALYs by (mean, 95% conﬁdence interval) 1.174 (1.02–1.30), 0.909
(0.79–1.01), 0.823 (0.71–0.91), and 0.453 (0.40–0.50) for MCP, CVP,
CHOP, and CHVP, respectively, compared with chemotherapy alone. The
incremental costs per QALY gained were £7474, £8621, £10,732, and
£8551, respectively. Sensitivity analyses indicated that rituximab plus
chemotherapy was a cost-effective treatment option, with incremental
cost-effectiveness ratios below a threshold of £30,000 per QALY gained.
When compared across the chemotherapy regimens, rituximab plus MCP
appeared to be the single most cost-effective treatment option, but further
randomized trials are required to substantiate this.
Conclusions: The addition of rituximab to chemotherapy in advanced FL
was found to be highly cost-effective in the UK.
Keywords: advanced follicular lymphoma, cost-effectiveness, cost-utility,
non-Hodgkin’s lymphoma, rituximab.
Introduction
Non-Hodgkin’s lymphoma (NHL) is a family of lymphoid neo-
plasms that includes over 20 discrete entities with characteristic
morphologic, immunophenotypic, genetic, and clinical features.
Follicular lymphoma (FL) accounts for 70% of indolent lympho-
mas and comprises approximately 30% of all NHL cases [1].
In the UK, NHL is the seventh most common cancer [2]. In 2005,
the incidence of NHL was approximately 17.1 per 100,000 of
the UK population [3].
Patients with FL typically present with disseminated disease
involving lymph node regions on both sides of the diaphragm
(stage III) or possibly involving 1 extra-lymphatic organs or
tissues (stage IV) [4,5]. For asymptomatic patients, a “watchful
waiting” approach is usually adopted [6,7], with a median time
to ﬁrst treatment of 31 months [8]. The disease course of FL is
characterized as slowly progressive, involving repeated relapses
and a median survival of 6–11 years, depending on the stage of
disease. Initial treatment of FL with chemotherapy can often
achieve a response, but the majority of patients relapse within 4
to 5 years.
The aim of FL management to date has been to increase
patient life expectancy and to maximize patient health-related
quality of life (QoL) by increasing the duration between episodes
of disease recurrence and by minimizing the symptoms associated
with relapse, as well as treatment side effects [9].
The most recent update to the rituximab license and mar-
keting authorization for ﬁrst-line treatment of FL is now less
prescriptive concerning the background chemotherapies with
which rituximab can be combined. Consequently, the license
now states “MabThera (rituximab) is indicated for the treat-
ment of previously untreated patients with stage III/IV FL in
combination with chemotherapy” [10]. This change will
increase the choice available to physicians when selecting the
underlying chemotherapy regimen in accordance with the spe-
ciﬁc needs of their patients.
The rituximab license change was informed primarily by the
results of four randomized phase III clinical trials where the
following combinations were evaluated: 1) rituximab plus mito-
xantrone, chlorambucil, and prednisolone (R-MCP) versus MCP
alone [11]; 2) rituximab plus cyclophosphamide, vincristine, and
prednisolone (R-CVP) versus CVP alone [12]; 3) rituximab plus
cyclophosphamide, doxorubicin, vincristine, and prednisolone
(R-CHOP) versus CHOP alone [13]; and 4) rituximab plus
cyclophosphamide, etoposide, doxorubicin, prednisolone, and
interferon alpha (R-CHVP + IFNa) versus CHVP + IFNa alone
[14].
Each phase III trial consistently showed superior disease out-
comes for the rituximab combination (R-chemotherapy) group
compared to chemotherapy alone. Speciﬁcally, a statistically sig-
niﬁcant improvement in overall response was seen in the R-MCP
group versus MCP alone (P = 0.0009), with progression-free sur-
vival (PFS) (P < 0.0001) and overall survival (OS) (P = 0.0096)
also in favor of the rituximab combination [11]. After a median
follow-up of 53 months, a signiﬁcant improvement in time to
treatment failure and OS was also demonstrated for R-CVP
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versus CVP alone, without an increase in clinically signiﬁcant
toxicity [12]. The primary endpoint of time to treatment failure
was statistically signiﬁcantly in favor of R-CHOP versus CHOP
alone (P = 0.001) [13]; all the secondary endpoints in this study
were also statistically signiﬁcant in favor of the rituximab com-
bination (including OS; P = 0.016). Five-year follow-up con-
ﬁrmed the beneﬁt in event-free survival of adding rituximab to
the combination of CHVP + IFNa compared with the base
regimen alone (P = 0.0004). There was also a statistically signiﬁ-
cant OS beneﬁt for the rituximab group in patients with high-risk
disease (P = 0.025) [14].
This study aimed to evaluate the lifetime health outcomes,
direct health service costs, and incremental cost-effectiveness of
R-chemotherapy compared to chemotherapy alone as ﬁrst-line
treatment for patients with follicular NHL in the UK. The evalu-
ation of cost-effectiveness was assessed using two different
approaches. The primary analysis involved assessing the cost-
effectiveness of the addition of rituximab to the underlying che-
motherapy alone, in four individual comparisons. Within this
comparison, it was assumed that the decision of which chemo-
therapy should be administered in combination with rituximab is
at the discretion of the physician. A secondary analysis was
performed that included a multiple treatment comparison, where
the total economic and clinical outcomes were ranked in a league
table.
Materials and Methods
Model
A cost-effectiveness analysis was carried out using a Markov
state-transition model to simulate the progression of patients
with follicular NHL over their lifetimes. The analysis was per-
formed from the perspective of the UK National Health Service.
In line with National Institute for Health and Clinical Excellence
recommendations, both health and economic outcomes were
discounted at 3.5% per annum [15].
Within the model, patients were assumed to be in one of three
discrete health states: PFS, progressed, or death (Fig. 1). It was
assumed that all patients enter the model in the PFS health state,
where study medication is initiated, i.e., patients receive a full
course of either R-chemotherapy or chemotherapy alone and are
evaluated for response. At the end of each month, a patient
within the PFS health state could stay in PFS, move to the
progressed state, or die (attributed to age-speciﬁc background
mortality). At the end of each month, patients in the progressed
health state could remain in the same state or die (attributed to
disease progression or background mortality). The progressed
health state was assumed to include the typical treatment
pathway for patients after disease progression after ﬁrst-line
therapy. Progressed patients were assumed to receive second- and
later-line therapies and to experience subsequent disease remis-
sions and relapses. This simplifying assumption avoided the com-
plexity arising from modeling the multiple remission and relapse
phases that patients normally experience, as well as the impact of
these treatment sequences [16].
It was assumed in the model that patients in the R-
chemotherapy arm gained the beneﬁts of treatment for the dura-
tion of time for which follow-up data were reported in the
respective trial publications. After the follow-up period, patients
in the R-chemotherapy treatment arm assumed the same risk of
progression as those receiving the baseline chemotherapy.
The model used a cycle length of 1 month and a half-cycle
correction was applied to the cyclical transitions to adjust for the
timing of the transition between health states. This adjustment
was intended to more accurately reﬂect the appropriation of both
health and economic outcomes in both the initial and ﬁnal cycles
within the model. The mean age of patients entering the model
was assumed to be 53 years (from the R-CVP vs. CVP trial),
which was broadly comparable to the mean age of patients
across all four clinical trials [12].
In the phase III studies used in this analysis, no new safety
signals were observed and rituximab did not add to the toxicity
of chemotherapy alone, therefore no difference in treatment-
related adverse events was accounted for in the model.
Clinical Data
Clinical trial data were taken from four randomized phase III
trials in patients with follicular NHL receiving ﬁrst-line treat-
ment. The trials compared the addition of rituximab to chemo-
therapy regimens of MCP, CVP, CHOP, or CHVP versus
chemotherapy alone. These trials were chosen as they informed
the rituximab license change. Equally important in this choice,
recent data indicate that these chemotherapy regimens are the
most commonly used to treat FL in the UK. Approximately 70%
of patients with follicular NHL received ﬁrst-line treatment with
R-CVP, 12% were treated with other chemotherapy regimens in
combination with rituximab (9% received R-CHOP), and 18%
were treated with chemotherapy only (i.e., no rituximab) [17]. As
access to patient-level data was not available for all these trials,
the Kaplan-Meier curves for PFS presented in the respective trial
publications were used to derive the monthly probability of
disease progression [18].
In the absence of patient-level data on the actual mean or
median duration of treatment administration, the maximum
treatment duration lengths reported in the study protocols or
publications were used. It was assumed that patients treated
with R-MCP/MCP received eight cycles of treatment, R-CVP/
CVP patients received eight cycles of treatment, R-CHOP/CHOP
patients received six cycles of treatment, R-CHVP + IFNa
patients received 6 cycles of CHVP with 18 months of IFNa, and
CHVP + IFNa patients received 12 cycles of CHVP and 18
months of IFNa.
A utility value between 0 and 1 was assigned to the modeled
health states to reﬂect decrements in patients’ QoL (where 1
represents perfect health and 0 death). Utility values elicited using
the EuroQoL ﬁve-dimensions questionnaire from a study that
included a cohort of 222 patients with follicular NHL in the UK
were therefore applied to the PFS and progressed health states
(Table 1) [19]. Uncertainties surrounding these point estimates
were tested in both one-way and probabilistic sensitivity analyses.
PFS
Progression
Death
Figure 1 Diagram of the three-state Markov model.
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Health State Probabilities
Progression-free survival health state. Transition probabilities
used to represent progression of the disease for the respective
chemotherapy regimens were calculated by ﬁtting either an expo-
nential or Weibull parametric function [25] to the Kaplan-Meier
PFS data of the chemotherapy alone arms obtained from the four
clinical trial publications (Table 2). These functions were chosen
to maintain the underlying assumption of proportional hazards.
The proportion of patients transitioning out of the PFS health
state at each cycle was calculated by taking the difference in the
cumulative probability of survival at a given time “t” and at
“t - 1.”
Hazard ratios were applied to the location parameters within
the respective parametric survival functions (under the assump-
tion of proportional hazards) to reﬂect the reduction in the
probability leaving PFS associated with the addition of rituximab
to the underlying chemotherapy. The respective hazard ratios
were calculated by taking a ratio of the cumulative hazard from
the R-chemotherapy and chemotherapy from the PFS Kaplan-
Meier curves. The cumulative hazard was calculated by summing
the negative log of the survival probabilities {H(t) = -S log[S(t)]}
for each treatment arm, restricted to the clinical follow-up
reported in the respective publications [25]. See Appendix S1
at http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i4_Ray.asp for details.
Results from the regression analyses indicated that the expo-
nential model provided the best unweighted ordinary least-
squares ﬁt to the Kaplan-Meier PFS data for the CVP, CHOP, and
MCP regimens (i.e., assessed by choosing the function with the
highest R2 values) and this was used in the base-case analysis
(Fig. 2). For the CHVP comparison, the Weibull function was
used as it provided the best ﬁt to the data (Table 2) [25]. The
impact of the selected parametric distributions used in the base-
case analysis on overall outcomes was tested in sensitivity
analyses.
Because of the small number of deaths that occurred in
patients in PFS during the clinical trials, it was not possible to
obtain reliable estimates of the mortality rates for these patients
directly from the data. Therefore, it was assumed that the prob-
ability of death for patients in the PFS health state was equal to
all-cause mortality from UK life tables [27]. The monthly prob-
ability of death according to the age-speciﬁc life tables was
multiplied by the proportion of patients remaining in the PFS
health state at each month, as determined by the parametric
function. The remainder of the patients leaving the PFS curve
were assumed to transition to the progressed health state.
Progressed health state. Patients in the progressed health state
were assumed to experience a series of relapses, subsequent lines
of treatment (after ﬁrst line), and disease remissions, with each
relapse involving different treatment options with different
health outcomes. Due to a paucity of data within the trials on
treatment sequences and their respective treatment beneﬁts,
average survival from time of ﬁrst relapse to death was calculated
Table 1 Probability distributions used in the probabilistic sensitivity
analyses
Model inputs Distribution and parameters Source
Health state utility for PFS Beta
a = 389, b = 94
(mean = 0.805; SE = 0.018)
[19,20]
Health state utility for
“Progression”
Beta
a = 46, b = 28
(mean = 0.618; SE = 0.056)
[19,20]
Monthly monitoring/surveillance
costs—PFS health state
Beta-PERT
Range: £27.46 to £41.20
(20% of mean = £ 34.33)
[21,22]
Monthly cost of medication in
progression health state
Beta-PERT
Range: £156.26 to £234.40
(20% of mean = £195.33)
[23]
Monthly monitoring/surveillance
costs—progression health
state
Beta-PERT
Range: £82.40 to £123.60
(20% of mean = £103.00)
[24]
Parametric model ﬁt to
chemotherapy Kaplan-Meier
PFS curves
Log Normal [20,25]
Probability of moving from
progressed health state to
death
Log Normal [20,26]
Hazard ratios applied to the
parametric functions to reﬂect
the treatment impact
Log Normal [20,25]
Costs are in UK sterling (2008).
PERT, program evaluation and review technique; PFS, progression-free survival; SE, standard
error.
Table 2 Transition probabilities, mortality probabilities, and hazard ratios
Markov transition Monthly probability mean (SE) Source
PFS to death Age-speciﬁc UK life tables [27]
Progression to death 0.0122 (0.0004) + age-speciﬁc Scotland and Newcastle Lymphoma Group [26]; UK life tables [27]
Parameters used to determine the distributions specifying the monthly probability of transitioning from PFS to progression or death (chemotherapy)*
Regimen l mean (SE) g mean (SE) Type of function
MCP -0.0213 (0.0004) NA Exponential
CVP -0.0446 (0.0005) NA Exponential
CHOP -0.0220 (0.0006) NA Exponential
CHVP 0.00178 (1.108) 1.6304 (0.0322) Weibull
Regimen Hazard ratio (SE)* Duration of treatment effect (months) Source
R-MCP 0.332 (0.226) 47 [11]
R-CVP 0.469 (0.146) 68 [12]
R-CHOP 0.394 (0.178) 35 [13]
R-CHVP 0.514 (0.165) 42 [14]
*Parameter estimates (l and g) of the functions were obtained by regression analysis of the Kaplan-Meier data from the respective clinical trials.
Parameterization of the functions:
Exponential = 1 - exp(-l ¥ time)
Weibull = 1 - exp(-l ¥ time^g).
For theWeibull function, monthly transitions are time dependent, whereas for the exponential function, monthly transitions are constant.
For probabilistic sensitivity analyses, the hazard ratios were sampled from a log normal distribution, with the standard errors estimated using the method described by Tudor et al. [28].
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; CHVP, cyclophosphamide, etoposide, doxorubicin, and prednisolone; CVP, cyclophosphamide, vincristine, and prednisolone;
MCP, mitoxantrone, chlorambucil, and prednisolone; NA, not available; R, rituximab; SE, standard error.
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based on outcomes reported by the UK-based Scotland and New-
castle Lymphoma Group registry of patients receiving second-
line treatment for follicular NHL (n = 249; 5-year follow-up)
[26]. These data were used to derive a monthly probability of
death after progression. Within the progressed health state, it was
assumed that this probability of death was equal in each treat-
ment arm (Table 2).
Costs
First-line medication costs. In the absence of patient-level data,
the mean doses administered in the trials were used to derive
monthly costs for each of the chemotherapy regimens except for
CHVP (Table 3). Owing to the lack of reported data on actual
treatment doses for CHVP, the per-protocol maximum recom-
mended doses were used to calculate the mean monthly costs of
the chemotherapy. The mean body weight and height (both of
which are used to calculate body surface area) were not reported
in the publications for R-CHOP versus CHOP, R-MCP versus
MCP, or R-CHVP versus CHVP. As a proxy, the values from the
trial reported by Marcus et al. [12] was used (Table 3).
Administration costs. The administration costs for the R-
chemotherapy and chemotherapy alone treatment regimens were
taken from the National Health Service reference costs [24], in
which there are ﬁve health resource groups (HRGs) for the
delivery of chemotherapy for neoplasm. Chemotherapy alone
was assigned HRG code X72.3 (delivery of simple parenteral
chemotherapy for neoplasm at ﬁrst attendance). R-chemotherapy
was assigned HRG code X72.1 (delivery of complex chemo-
therapy for neoplasm including prolonged infusional treatment
at ﬁrst attendance). It was assumed that both R-chemotherapy
and chemotherapy alone were administered in an inpatient
setting. Based on this assumption, the administration cost for
chemotherapy alone was calculated to be £309 per month and
the cost for R-chemotherapy was £430 per month.
Drug Costs for Progressed Health State
Owing to limited access to data on the post-progression treat-
ments received by patients, trial-speciﬁc values could not be
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Figure 2 Survival curves: comparison of the observed PFS Kaplan-Meier curves with the predicted parametric extrapolation of the PFS and estimated OS.
Table 3 Mean monthly medication costs for the ﬁrst-line treatment
regimens
Regimen Cost (£)
MCP 113.46
R-MCP 950.17
CVP 25.37
R-CVP 862.08
CHOP 215.53
R-CHOP 1331.15
CHVP + IFNa (ﬁrst 6 months)* 619.51
R-CHVP + IFNa (ﬁrst 6 months)* 1735.14
CHVP + IFNa (second 6 months) 456.92
R-CHVP + IFNa (second 6 months) 294.32
*Medication costs were derived from Monthly Index of Medical Specialties [29]. For CHVP
the maximum recommended per-protocol doses were used to calculate the mean monthly
costs of the CHVP.
Actual mean doses administered were used to derive monthly costs for each of the
chemotherapy regimens except for CHVP.
Costs are UK sterling (2008).
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; CHVP, cyclophospha-
mide, etoposide, doxorubicin, and prednisolone; CVP, cyclophosphamide, vincristine, and
prednisolone; IFNa, interferon alpha; MCP, mitoxantrone, chlorambucil, and prednisolone;
R, rituximab.
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derived. Therefore, the monthly drug costs for patients in the
progressed health state of the model were based on published
literature [23]. Tolley et al. [23] evaluated the potential treatment
sequences for patients with FL in the UK and estimated a corre-
sponding “expected” lifetime drug cost. This cost of £13,145
(undiscounted) was inﬂated to 2008 prices (£13,145 ¥ 1.21 =
£15,940) and then divided by the expected remaining lifetime
survival for patients with FL (6.8 years) to obtain an average
annual drug cost of £2344 per patient [21,30]. This cost was then
divided by 12 (£195) and applied to each monthly cycle of the
model. Uncertainty around estimated treatment costs for pro-
gressed patients was explored in one-way sensitivity analyses.
Cost of routine management/surveillance. To reﬂect the fre-
quency of nonmedication-related medical visits, it was assumed
that patients with FL would incur costs of routine management/
surveillance during each cycle of the model. For simplicity and to
avoid double counting of costs captured in other sections of the
economic evaluation (e.g., treatment costs upon relapse and drug
administration), the routine management costs consisted of out-
patient monitoring visits only. Patients in the progressed health
state were assigned a cost of an outpatient visit every month
(£103 [24]) [21]. Patients who were in the PFS state were attrib-
uted the cost of an outpatient visit every 3 months (£34.33 per
cycle; £103/3). The frequency of surveillance was based on a
publication [22], as utilized by Knight et al. [31], which esti-
mated a routine check-up every 3 to 4 months for PFS.
Sensitivity analyses. Sensitivity analyses were performed to
investigate the impact that changes in the key input parameters
and assumptions had on the results of the base-case analyses.
Univariate sensitivity analyses were performed on a range of
parameters including utility values, rate of disease progression,
time horizon, and the cost of medication and monitoring. Prob-
ability distributions were used in the model to test the uncer-
tainty surrounding parameters in a probabilistic sensitivity
analysis (Table 1).
Results
Individual Treatment Comparison
Health outcomes. In the base-case analysis, the addition of rit-
uximab to MCP, CVP, CHOP, and CHVP was projected to
improve mean discounted life expectancy by 1.357, 1.054,
0.955, and 0.528 years (undiscounted 1.927, 1.437, 1.334, and
0.721 years), respectively, compared with chemotherapy alone
(Table 4).
Similar improvements were observed after adjusting for
health-related QoL with incremental discounted quality adjusted
life expectancy estimated to increase by 1.184, 0.914, 0.831, and
0.458 years after the addition of rituximab to MCP, CVP, CHOP,
and CHVP, respectively (Table 4).
Economic outcomes. The addition of rituximab treatment to
MCP, CVP, CHOP, and CHVP was projected to result in total
discounted direct costs of £29,725, £28,582, £29,794, and
£33,513, respectively, compared with £20,900, £20,708,
£20,922, and £29,621 for MCP, CVP, CHOP, and CHVP alone,
respectively (Table 4). Treatment with rituximab was estimated
to increase incremental total direct medical costs by £3892 to
£8872. Medication costs after progression made up the largest
proportion of the total cost in both the R-chemotherapy and
chemotherapy treatment arms across all comparisons (Fig. 3).
Incremental cost-effectiveness. The incremental cost-
effectiveness ratios (ICERs) were estimated to be £6503, £7473,
£9294, and £7370 per life-year gained with the addition of
rituximab to MCP, CVP, CHOP, and CHVP, respectively. When
health-related QoL was taken into account, ICERs ranged from
£7455 to £10,676 per quality-adjusted life-year (QALY) gained
for the addition of rituximab to the chemotherapy regimens
(Table 4).
One-way sensitivity analyses. One-way sensitivity analyses per-
formed on the primary input parameters indicated that the
results were robust under a wide range of plausible assumptions
(Table 5). The one-way sensitivity analyses indicated that results
were most sensitive to the time horizon applied. This assumption
was evaluated in two ways. Firstly, by calculating results using
the parametric extrapolation restricted to time horizons of 5 and
10 years, and secondly, by limiting the time horizon to the
duration of the respective Kaplan-Meier PFS survival curves (i.e.,
the period of time for which follow-up data were available with
no parametric extrapolation). Assuming a time horizon of 5
years, ICERs for the addition of rituximab to chemotherapy
versus chemotherapy alone ranged from £17,027 to £26,628 per
QALY gained. These ICERs were £9,195 to £13,426 per QALY
Table 4 Summary of base-case (deterministic) results*
Comparators
Time in health state (years) Total
Cost (£)
ICERs
PFS Progression QALY LY £/QALY gained £/LY gained
R-MCP 5.306 4.006 6.747 9.312 29,725 — —
MCP 3.460 4.494 5.563 7.954 20,900 — —
Incremental 1.845 -0.488 1.184 1.357 8,826 7,455 6,503
R-CVP 3.175 4.588 5.392 7.764 28,582 — —
CVP 1.768 4.942 4.748 6.710 20,708 — —
Incremental 1.407 -0.393 0.914 1.054 7,874 8,613 7,473
R-CHOP 4.656 4.186 6.335 8.842 29,794 — —
CHOP 3.367 4.520 5.504 7.887 20,922 — —
Incremental 1.289 -0.335 0.831 0.955 8,872 10,676 9,294
R-CHVP 4.052 4.376 5.966 8.428 33,513 — —
CHVP 3.348 4.552 5.508 7.900 29,621 — —
Incremental 0.704 -0.176 0.458 0.528 3,892 8,498 7,370
*All health and economic outcomes were discounted at 3.5% per annum over patient lifetimes.
Costs are UK sterling (2008).
Incremental = R-chemotherapy vs. chemotherapy alone.
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; CHVP, cyclophosphamide, etoposide, doxorubicin, and prednisolone; CVP, cyclophosphamide, vincristine, and prednisolone;
ICERs, incremental cost-effectiveness ratios; LY, life-year; MCP, mitoxantrone, chlorambucil, and prednisolone; PFS, progression-free survival; QALY, quality adjusted life-year; R, rituximab.
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gained with a 10-year time horizon. When the analysis was
limited to the duration of the Kaplan-Meier survival data, ICERs
varied from £9427 to £31,678 per QALY gained. The impact
of including additional costs associated with treating adverse
events and infusion site reactions on the overall cost-effectiveness
was investigated by increasing the costs applied in the R-
chemotherapy treatment arms (please see the Supporting Infor-
mation Appendix S2 for this article at http://www.ispor.
org/Publications/value/ViHsupplementary/ViH13i4_Ray.asp).
Results suggested that the incremental costs of treating
adverse events and infusion site reactions would need to increase
beyond £10,000 for the addition of rituximab to the standard
chemotherapy regimens to approach ICERs above those com-
monly considered cost-effective.
It is important to note that in only one case did the discounted
incremental cost per QALY increase above a £30,000 willingness
to pay threshold (approximately £31,000 for R-CHOP vs.
CHOP over the 35-month duration of the Kaplan-Meier survival
data).
Probabilistic sensitivity analysis. A probabilistic sensitivity
analysis (second-order Monte Carlo simulation; 1000 iterations)
was also performed, which involved randomly sampling from
distributions describing the uncertainty around point estimates
used in the deterministic base-case analysis. Distributions were
applied to the costs of the progressed health state (medication
and monitoring/surveillance costs), monitoring/surveillance costs
incurred in the PFS health state, utility values, hazard ratios, and
Figure 3 Breakdown of total direct health-care costs.
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upper and lower bounds of the 95% conﬁdence intervals sur-
rounding the transition probabilities from the parametric regres-
sion analysis (Tables 1 and 4). Given the small standard error
estimates of the parameters determining the probability of
disease progression and death (after progression), further analy-
sis was conducted where the uncertainty around these estimates
was increased to correspond with the asymptotic standard errors
under the assumption of an exponential distribution [12]. The
additional uncertainty was introduced, and the incremental dis-
counted quality adjusted life expectancy and total cost calcula-
tions of 1000 different simulations were used to create scatter
plot diagrams (Fig. 4). Acceptability curves generated from
these plots (please see the Supporting Information Appendix S2
for this article at http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i4_Ray.asp) conﬁrmed that there was
a very high probability that R-chemotherapy would be a cost-
effective treatment option versus chemotherapy alone, assuming
a willingness to pay threshold of £20,000 per QALY gained.
Multiple Treatment Comparison
To explore which ﬁrst-line FL treatment was the single most
cost-effective option from the eight different therapies assessed, a
multiple treatment comparison using a cost-effectiveness league
table was developed. The treatment options were initially ranked
by their total estimated lifetimes costs (from the base-case analy-
sis) (Table 6) [32]. Incremental costs and effects (QALYs) were
then calculated. A treatment with smaller effects than the pre-
ceding treatment in the table was eliminated from the compari-
son as they were determined to be “dominated” by the (higher
costs and lower effects) previous treatment. Results were plotted
in an efﬁciency frontier (Fig. 5).
Base-Case
Rankings for the table started with CVP as this was estimated to
be the least costly treatment option considered in the analysis.
Treatment with MCP has the second lowest costs and in com-
parison to the incremental costs and effects, was determined to be
cost-effective compared to CVP, with an ICER of £235 per QALY
gained. The following three treatments (CHOP, CHVP, and
R-CVP) were estimated to be dominated by treatment with MCP
(higher costs and lower overall QALYs). Compared to MCP,
R-MCP was estimated to be cost-effective, with a corresponding
ICER of £7454, consistent with the results of base-case analysis.
Treatments with either R-CHOP or R-CHVP were both domi-
nated by R-MCP.
Given that each of the clinical studies used in the base-case
analysis had a different time period of follow-up, these results
should be interpreted with caution. This shortcoming was
addressed by restricting the treatment effect in each of the
R-chemotherapy arms to 53 months.
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Figure 4 Scatter plot diagram: incremental costs versus incremental QALYs.
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Treatment Effect for R-Chemotherapy Restricted for
53 Months
An additional league table was prepared in a subsequent sce-
nario where the treatment effect (hazard ratio) for all
R-chemotherapy options was applied for 53 months, using
results from one of the sensitivity analyses presented in Table 5.
Rankings of the total lifetime costs indicated that treatment
with CVP was the lowest, followed by MCP (Table 7). Using
incremental values, MCP was cost-effective compared to CVP
(corresponding to an ICER of £235 per QALY gained). Treat-
ment with CHOP and R-CVP were dominated by MCP.
R-CHOP was cost-effective compared to MCP (with an ICER
of £7976 per QALY gained), and R-MCP was determined to be
cost-effective versus R-CHOP (with an ICER of £479 per
QALY gained). Treatments with either CHVP or R-CHVP were
both dominated by R-MCP. Treatment with R-CHOP was
subject to “extended dominance” where a combination of
treatment with R-MCP and MCP could be more efﬁcient. This
conclusion would imply that these treatments are perfectly
divisible with constant returns to scale, with the assumption
that a certain proportion of patients could be distributed to
receive either R-MCP or MCP, and if so, the beneﬁts of treat-
ment with either regimen would return the same estimates of
cost-effectiveness [32].
Discussion
The primary economic evaluation involved assessing the cost-
effectiveness of the addition of rituximab to chemotherapy in
four individual comparisons. This was based on four phase III
randomized trials that consistently showed superior disease out-
comes for patients with FL treated with R-chemotherapy com-
pared to chemotherapy alone [11–14]. Based on parametric PFS
survival analysis of these trials over the lifetime of patients, this
model predicted a mean increase in discounted life expectancy of
1.357, 1.054, 0.955, and 0.528 years for R-MCP, R-CVP,
R-CHOP, and R-CHVP patients, respectively, when compared
with the chemotherapy regimens alone. Variations in incremental
life expectancy were attributed to differences in the assumed
duration of the treatment beneﬁt of rituximab across each evalu-
ation (i.e., the length of time the hazard ratio was applied in each
of the comparisons), due to variations in the duration of
follow-up data reported in the publications.
The difference in the predicted life-years gained across the
four models can be explained largely by the assumed duration of
treatment beneﬁt, which in turn is related to the duration of
follow-up reported from each trial. The impact of adverse events
(both clinically and economically) was not included in this eco-
nomic evaluation, as no clinically signiﬁcant difference between
the rate and/or severity of adverse events was observed between
treatment arms in any of the four clinical trials. Patient health
state utilities from Pettengell et al. [19] were used to estimate the
incremental QALYs gained for R-MCP, R-CVP, R-CHOP, and
R-CHVP (1.184, 0.914, 0.831, 0.458 years, respectively). This
ﬁnding is mainly related to the QALYs gained due to the longer
time in the PFS health state (~0.7–1.8 years) resulting from the
slower rate of disease progression for the patients treated with
R-chemotherapy than observed for patients treated with the cor-
responding chemotherapy alone.
Table 6 Cost-effectiveness league table (across chemotherapy regimens, using base-case results)
Regimen Cost (£)
Incremental
cost (£)
Effect
(QALYs)
Incremental
effect (QALYs)
Cost-
effectiveness
Incremental
cost-effectiveness
CVP 20,708 — 4.748 — 4,361 —
MCP 20,900 192 5.563 0.815 3,757 235
CHOP* 20,922 22 5.504 -0.059 3,801 Dominated
R-CVP* 28,582 7,682 5.392 -0.171 5,301 Dominated
CHVP* 29,621 8,721 5.508 -0.055 5,378 Dominated
R-MCP* 29,725 8,825 6.747 1.184 4,406 7,454
R-CHOP† 29,794 69 6.335 -0.412 4,703 Dominated
R-CHVP† 33,513 3,788 5.966 -0.781 5,617 Dominated
*Compared to MCP; †Compared to R-MCP, R, Ritxuimab.
Figure 5 Cost-effectiveness Frontier: multiple treatment comparison (across chemotherapy regimens).
354 Ray et al.
Total direct costs were higher in the R-chemotherapy treat-
ment arms, primarily attributed to the acquisition cost of ritu-
ximab. Nevertheless, due to the increased length of time spent in
the progressed health state for patients treated with chemo-
therapy alone, the increased total direct medical costs associated
with rituximab were projected to be partially offset by reductions
in both the total medication costs and monitoring/surveillance
costs incurred in the progressed health state.
The base-case incremental costs per QALY gained of £7455,
£8613, £10,676, £8498 for R-MCP, R-CVP, R-CHOP, and
R-CHVP, respectively, for the individual treatment comparison,
appears relatively stable after one-way sensitivity analyses for all
major model parameters (Table 5). When uncertainty was
explored using probabilistic sensitivity analysis, values consis-
tently fell below the willingness to pay thresholds commonly
used in the UK. Rituximab in combination with chemotherapy in
the ﬁrst-line treatment of FL can therefore be considered a cost-
effective therapy with a high degree of certainty.
The only instance in which the incremental cost per QALY
gained for R-chemotherapy versus chemotherapy alone was
above £30,000 willingness to pay threshold was when the analy-
sis was limited to the 35 months of the Kaplan-Meier PFS data
for R-CHOP versus CHOP alone. It is important to note that this
scenario does not incorporate a lifetime horizon and therefore
does not follow normal economic evaluation best practice by
accounting for all expected costs and beneﬁts [33]. Indeed, when
the duration of the treatment beneﬁt of R-CHOP versus CHOP
was increased from 35 months to 53 months (in line with the
duration of follow-up in the R-CVP clinical study [13]), the ICER
decreased from £10,676 to £7545 per QALY gained (Table 5).
Within the multiple treatment comparison approach, the
addition of rituximab to MCP was estimated to be the single
most cost-effective option from the eight different ﬁrst-line FL
treatments assessed in the base-case and also when the same
treatment effect was applied to all R-chemotherapy options.
Although this multiple treatment comparison using a cost-
effectiveness league table is a simple approach to identifying the
most cost-effective treatment option, it has limitations. For
example, comparing across the different underlying chemo-
therapy arms carries the assumption that the patient populations
in the various studies were homogenous in the study methodol-
ogy and outcomes were comparable. Nevertheless, in the clinical
trials, there differences in the gender distribution, median age
(mean not consistently report) and the different treatment cycle
lengths studied. A more robust approach to comparing across
these treatments would require a mix-treatment comparison
where the available evidence would be systematically reviewed
into a connected network, in which the individual results are
pooled and adjusted to provide rankings of their comparative
effectiveness [34,42]. To date, only two of the eight chemo-
therapy regimens were comparable, highlighting the need for
further randomized trials to inform such analyses. Future analy-
ses would need to account for possible interactions between the
different medications comprising the various chemotherapy com-
binations and variation in the cycle lengths.
The Markov model used in this economic evaluation is
similar in structure to that used in another recently published
study, which also showed that R-CVP is cost-effective versus
CVP alone (baseline discounted incremental cost per QALY
gained of $28,561) in the ﬁrst-line treatment of advanced FL in
the US [35]. The present study differed from that by Hornberger
et al. in that the costs of rituximab infusion reactions were not
included and patients were assumed to receive the full course of
treatment (i.e., R-chemotherapy or chemotherapy alone). Never-
theless, in sensitivity analyses, the effect of varying treatment
administration costs, adverse event, and infusion site reaction
costs was not found to change the cost-effectiveness conclusions
for R-chemotherapy versus chemotherapy alone. Owing to the
considerably higher cost of R-chemotherapy versus chemo-
therapy alone, the assumption that patients receive the full course
of treatment, without taking into account the possibility of
patients stopping treatment early, can be considered to be a
conservative assumption. Another distinction is that the earlier
economic evaluation by Hornberger et al. was based on the
40-month follow-up data of the clinical trial comparing R-CVP
versus CVP [36], whereas the present analysis uses the more
recently published 53-month follow-up data to inform the prob-
ability of remaining in the PFS health state for both treatments
arms. Additionally, by including other commonly administered
ﬁrst-line chemotherapy regimens in the economic evaluation, it is
intended to expand upon conclusions drawn by earlier economic
evaluations of rituximab.
Due to of the paucity of data on the disease process and
treatment patterns after progression after ﬁrst-line therapy, the
impact of assumptions made in the base-case was explored in
sensitivity analyses. Consistent with existing clinical trial proto-
cols demonstrating the effect of rituximab in patients receiving
ﬁrst-line treatment for indolent NHL, we assumed that rituximab
is used only as a ﬁrst-line therapy option, excluding its use as
“maintenance therapy” or in combination with other later-line
treatments. Modeling economic or survival beneﬁts in the case of
maintenance therapy requires a different approach and addi-
tional clinical data. In this clinical situation, rituximab has also
been shown to be a cost-effective treatment option [37,38].
Time to disease progression was modeled parametrically with
either an exponential and Weibull function, using ordinary least
squares regression methods. In the case of the exponential func-
tion unknown parameter, lambda (l), was estimated by regress-
ing the negative log of survival versus time; whereas in the case of
the Weibull, the unknown parameters, lambda (l) and gamma
(g), were estimated by regressing the log of the negative log of
survival versus the log of time. The underlying assumption of
Table 7 Cost-effectiveness league table (across chemotherapy regimens, assuming duration of R-chemotherapy treatment effect for 53 months)
Regimen Cost (£)
Incremental
cost (£)
Effect
(QALYs)
Incremental
effect (QALYs)
Cost-
effectiveness
Incremental
cost-effectiveness
CVP 20,708 — 4.748 — 4,361 —
MCP 20,900 192 5.563 0.815 3,757 235.58
CHOP* 20,922 22 5.504 -0.059 3,807 Dominated
R-CVP* 28,664 7,764 5.297 -0.266 5,411 Dominated
R-CHOP* 29,514 8,614 6.643 1.08 4,443 7,976
R-MCP 29,618 104 6.860 0.217 4,318 479
CHVP† 29,621 3 5.508 -1.352 5,378 Dominated
R-CHVP† 33,420 3,802 6.081 -0.779 5,496 Dominated
*Compared to MCP; †Compared to R-MCP, R, Ritxuimab.
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proportional hazards assumed in the Kaplan-Meier analysis was
maintained when modeled parametrically. The absence of patient
level data resulted in an underestimation of the standard errors of
the parameters for the exponential and Weibull functions. Sen-
sitivity analyses were performed to address this issue by increas-
ing the uncertainty in the standard error estimates in both the
exponential and Weibull functions. The results of these analyses
indicated that the overall probability of rituximab a cost-
effectiveness addition to the chemotherapies included in the
analysis remained stable [25,39].
We also assumed that disease progression after ﬁrst-line treat-
ment could be adequately represented by a single health state
(progressed), which takes into account the multiple cycles of
relapse, later-line treatments, and remissions experienced by
patients with FL. One-way sensitivity analyses demonstrated that
in all the cases where high assumptions were used for progression
parameters (i.e., the rate of mortality, monthly cost of progressed
monitoring/surveillance and medication), R-chemotherapy
remained a cost-effective option when compared with chemo-
therapy alone.
Unlike aggressive lymphomas, the use of autologous stem cell
therapy (SCT) in the treatment of patients with indolent NHL
has not yet been fully established in the UK [40]. Autologous
SCT could be provided as consolidation treatment after response
to second line therapy. Monthly costs applied to the progressed
health state in the base-case analysis were derived from a costing
study of FL patients in the UK. This study reported that the use
of SCT could increase lifetime costs to over £15,000 (inﬂated to
2008 values) [23]. Given potential uncertainty in the frequency
of SCT use (allograft bone marrow transplantation) since the
publication of the costing, further sensitivity analysis was per-
formed to investigate the impact of including these costs in the
model. The UK National Schedule of Reference Costs lists the
cost of bone marrow transplantation to be ~£50,653, increasing
the cost per patient to £66,593 over 6.8 years corresponding to
a monthly state cost of £816. The model estimated that patients
in the chemotherapy alone treatment arms spent more time in the
progressed health state than R-chemotherapy patients. As a
result, increasing the costs of the progressed health state lowered
the ICERs below that reported in the base-case, in all four
scenarios. Further studies in the UK similar to a recent analysis
performed in The Netherlands of NHL treatment strategies by
line of therapy would be beneﬁcial in informing the likely cost of
SCT and lifetime treatment costs for future health economic
studies [41]. Nevertheless, the model appears to be relatively
insensitive to this parameter.
In summary, the evidence from this modeling analysis
strongly indicates that when compared directly to the underlying
chemotherapy regimen, the addition of rituximab increased both
life expectancy and quality-adjusted life expectancy, and is a
highly cost-effective treatment option for patients with advanced
FL from a UK perspective. When compared across the chemo-
therapy regimens, R-MCP appeared to be the single most cost-
effective treatment option, but further randomized trials are
required to substantiate this.
This study was funded by F. Hoffmann-La Roche, Ltd.
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